1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?

The multiple sclerosis market is arguably one of the most competitive in pharma, shaped in part by a handful of products (Avonex, Betaseron, Copaxone and Rebif) that are both effective, very well established and which deliver broadly comparable efficacy. In more recent years, an 'oral revolution' has advanced the therapeutic optionality for MS patients, but simultaneously left room for further improvements.

As patients await the next generation of therapies to emerge from the clinic – potentially improving care in certain subtypes of the disease or facilitating the repair of damage caused by MS – another dynamic is likely to emerge via the potential launch of generic Copaxone products.

Despite the competitive nature of this disease market, prices for MS drugs have risen notably in recent years; a recently published (by Bloomberg) list of 73 drugs that have seen a US list price increase of 75 percent or more since 2007 included five of the most widely prescribed MS drugs.

With the potential launch of generic Copaxone set to provide some form of platform for pricing pressure, will other factors that have driven brand loyalty in MS be overlooked or will the dynamics that have allowed this therapy to persist as one the strongest growing in recent years remain in place?

Against this backdrop, FirstWord polled 186 neurologists based in the US and EU5 to ask them a series of questions about their approach to using MS therapies. Specifically we asked them...

- How they rate their personal level of loyalty to the MS treatments they prescribe?
- In what segment of the MS market is their loyalty to particular products strongest?
- What a new therapy would need to demonstrate versus existing treatments to change their prescribing habits?
- What clinical attribute (apart from efficacy) they believe is the most important differentiator between approved MS therapies?
- What commercial attribute they believe is the most important differentiator between approved MS therapies?

Table Of Contents

Physician Views: What drives physician brand loyalty in the ultra-competitive multiple sclerosis market?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19 Summary Cancer vaccines are being ...

Protein Therapeutics Market Analysis and Trends- Therapeutic Proteins (Bone morphogenetic proteins, Interferon (IFN), Insulin and Engineered protein scaffolds), Application (Cancer and Fertility), Function  - Forecast to 2025

Protein Therapeutics Market Analysis and Trends- Therapeutic Proteins (Bone morphogenetic proteins, Interferon (IFN), Insulin and Engineered protein scaffolds), Application (Cancer and Fertility), Function - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Protein Therapeutics Devices Market is poised to grow at a CAGR of around 8.6% over the next decade to reach approximately $315.90 billion by 2025. Some of the prominent trends that the market ...

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Pipel

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Receptor Type I or ALK5 or TGFBR1 or EC 2.7.11.30) - Pipel

  • $ 3500
  • Industry report
  • August 2016
  • by Global Markets Direct

TGF Beta Receptor Type 1 (Activin A Receptor Type II Like Protein Kinase Of 53kD or Activin Receptor Like Kinase 5 or Serine/Threonine Protein Kinase Receptor R4 or Transforming Growth Factor Beta Recepto ...


Download Unlimited Documents from Trusted Public Sources

Global Therapy Market

  • November 2016
    8 pages
  • Vaccine  

  • World  

    Nigeria  

    Pakistan  

View report >

Global Therapy Market, Weekly Update

  • November 2016
    12 pages
  • Vaccine  

    Infectious Dise...  

  • World  

    United States  

View report >

Global Therapy Market - Forecast

  • November 2016
    2 pages
  • HPV Vaccine  

    Vaccine  

    Cervical Cancer  

  • Ireland  

    World  

    Australia  

View report >

Global Therapy Market

1 month ago

Related Market Segments :

Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.